Page last updated: 2024-12-06

p-chloro-o-toluidine hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

p-chloro-o-toluidine hydrochloride: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID18487
CHEMBL ID3182298
SCHEMBL ID131186
MeSH IDM0555395

Synonyms (86)

Synonym
azogene fast red tr
4-chloro-o-toluidine.hcl
c.i. 37085
nsc7629
devol red k
devol red ta salt
fast red salt tra
fast red salt tr
devol red tr
nsc-7629
kromon green b
4-chloro-2-methylaniline hydrochloride
fast red 5ct salt
azoic diazo component 11 base
brentamine fast red tr salt
azanil red salt trd
4-chloro-2-methylbenzenamine hydrochloride
3165-93-3
c.i. azoic diazo component 11
4-chloro-o-toluidine hydrochloride
hindasol red tr salt
fast red tr salt
p-chloro-o-toluidine hydrochloride
red trs salt
neutrosel red trva
4-chloro-o-toluidine (nh2=1) hydrochloride
red salt ciba ix
red salt irga ix
amarthol fast red tr salt
4-chloro-6-methylaniline hydrochloride
5-chloro-2-aminotoluene hydrochloride
2-amino-5-chlorotoluene hydrochloride
azoene fast red tr salt
nci-c02368
natasol fast red tr salt
diazo fast red tr
4-chloro-o-toluidine (nh2=1)
daito red salt tr
fast red salt trn
2-methyl-4-chloroaniline hydrochloride
wln: zr dg b1 &gh
chlorhydrate de 4-chloroorthotoluidine
4-chloro-2-toluidine hydrochloride
ofna-perl salt rra
sanyo fast red salt tr
ci azoic diazo component 11
nsc 7629
o-toluidine, 4-chloro-, hydrochloride
un1579
chlorhydrate de 4-chloroorthotoluidine [french]
amarthol fast red tr
rcra waste number u049
asymmetric meta-chloro-ortho-toluidine hydrochloride
clorhidrato de 4-cloro-o-toluidine
rcra waste no. u049
ccris 153
benzenamine, 4-chloro-2-methyl-, hydrochloride
hsdb 6191
chlorhydrate de chloro-4 o-toluidine
einecs 221-627-8
4-chloro-o-toluidinium chloride
4-chloro-o-toluidine hydrochloride [un1579] [poison]
unii-1y82dn556p
1y82dn556p ,
benzenamine, 4-chloro-2-methyl-, hydrochloride (1:1)
4-chloro-o-toluidine hcl
cas-3165-93-3
NCGC00256591-01
tox21_302920
dtxcid20288
dtxsid0020288 ,
NCGC00258835-01
tox21_201283
FT-0618236
4-chloro-o-toluidine hydrochloride [hsdb]
SCHEMBL131186
2 -amino-5 -chlorotoluene hydrochloride
VKYZDCTWJGBFDW-UHFFFAOYSA-N
AKOS016846210
CHEMBL3182298
4-chloro-2-methylaniline hydrochloride, aldrichcpr
J-018507
Q27253163
4-chloro-2-methylaniline;hydrochloride
D89231
4-chloro-o-toluidinehydrochloride

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" 4-CloT was administered orally over 28 consecutive days (days 1-28), followed by a 28-day treatment-free (days 29-56), and a second dosing phase of 3 days (days 57-59)."( DNA Damage Response of 4-Chloro-Ortho-Toluidine in Various Rat Tissues.
Christen, F; Funk, J; Guérard, M; Marchand, C; Winter, M; Zeller, A, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency40.85620.000714.592883.7951AID1259392
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency53.60690.001022.650876.6163AID1224838; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency76.72090.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency22.97520.001530.607315,848.9004AID1259401
estrogen nuclear receptor alphaHomo sapiens (human)Potency4.36470.000229.305416,493.5996AID743069
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency21.87510.023723.228263.5986AID743223
aryl hydrocarbon receptorHomo sapiens (human)Potency29.70110.000723.06741,258.9301AID743085; AID743122
heat shock protein beta-1Homo sapiens (human)Potency60.49180.042027.378961.6448AID743210; AID743228
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (28.57)18.7374
1990's8 (38.10)18.2507
2000's4 (19.05)29.6817
2010's3 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.32 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]